The spectrum of GATA2 deficiency syndrome
Blood · 30.03.2023 · 141 (13) · 1524-1532
DOI: 10.1182/blood.2022017764 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, erschienen am 30.03.2023. Verfasst von Katherine R Calvo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, National Institutes of Health Clinical Center, Bethesda, MD. Hauptthemen laut MEDLINE: GATA2 Deficiency, Myelodysplastic Syndromes, Myeloproliferative Disorders. Die Arbeit wurde bisher 99-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CCR NIH HHS, NCI NIH HHS, Intramural NIH HHS.
Abstract (Originalsprache)
Inherited or de novo germ line heterozygous mutations in the gene encoding the transcription factor GATA2 lead to its deficiency. This results in a constellation of clinical features including nontuberculous mycobacterial, bacterial, fungal, and human papillomavirus infections, lymphedema, pulmonary alveolar proteinosis, and myelodysplasia. The onset, or even the presence, of disease is highly variable, even in kindreds with the identical mutation in GATA2. The clinical manifestations result from the loss of a multilineage progenitor that gives rise to B lymphocytes, monocytes, natural killer cells, and dendritic cells, leading to cytopenias of these lineages and subsequent infections. The bone marrow failure is typically characterized by hypocellularity. Dysplasia may either be absent or subtle but typically evolves into multilineage dysplasia with prominent dysmegakaryopoiesis, followed in some instances by progression to myeloid malignancies, specifically myelodysplastic syndrome, acute myelogenous leukemia, and chronic myelomonocytic leukemia. The latter 3 malignancies often occur in the setting of monosomy 7, trisomy 8, and acquired mutations in ASXL1 or in STAG2. Importantly, myeloid malignancy may represent the primary presentation of disease without recognition of other syndromic features. Allogeneic hematopoietic stem cell transplantation (HSCT) results in reversal of the phenotype. There remain important unanswered questions in GATA2 deficiency, including the following: (1) Why do some family members remain asymptomatic despite harboring deleterious mutations in GATA2? (2) What are the genetic changes that lead to myeloid progression? (3) What causes the apparent genetic anticipation? (4) What is the role of preemptive HSCT?
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, National Institutes of Health Clinical Center, Bethesda, MD.
- Immune Deficiency - Cellular Therapy Program, National Cancer Institute, National Institutes of Health, Bethesda, MD.
ORCID-Profile: Dennis D Hickstein
Förderung
- CCR NIH HHS
- NCI NIH HHS
- Intramural NIH HHS
Zitieren
APA
Calvo, K. R., & Hickstein, D. D. (2023). The spectrum of GATA2 deficiency syndrome. Blood, 141(13), 1524-1532. https://doi.org/10.1182/blood.2022017764
Vancouver
Calvo KR, Hickstein DD. The spectrum of GATA2 deficiency syndrome. Blood. 2023;141(13):1524-1532. doi:10.1182/blood.2022017764
BibTeX
@article{Calvo2023,
author = {Calvo, Katherine R and Hickstein, Dennis D},
title = {The spectrum of GATA2 deficiency syndrome},
journal = {Blood},
year = {2023},
volume = {141},
number = {13},
pages = {1524--1532},
doi = {10.1182/blood.2022017764}
}
EUVIMED